News stories about Momenta Pharmaceuticals (NASDAQ:MNTA) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.2413970790822 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) traded up 1.917% on Monday, reaching $17.275. The company had a trading volume of 496,092 shares. The company’s 50 day moving average price is $16.28 and its 200-day moving average price is $15.45. The stock’s market capitalization is $1.28 billion. Momenta Pharmaceuticals has a 1-year low of $10.75 and a 1-year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million during the quarter, compared to the consensus estimate of $24.64 million. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. The company’s quarterly revenue was down 10.8% compared to the same quarter last year. Equities analysts predict that Momenta Pharmaceuticals will post ($1.24) EPS for the current year.

MNTA has been the topic of a number of recent research reports. Stifel Nicolaus restated a “buy” rating and set a $26.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Barclays PLC downgraded Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $20.00 to $17.00 in a research report on Monday, May 22nd. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Maxim Group set a $6.00 target price on Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $16.63.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/11/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-momenta-pharmaceuticals-mnta-stock-price.html.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now directly owns 269,231 shares in the company, valued at $4,057,311.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 43,996 shares of company stock worth $735,755 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.